AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter 2024. The London-listed company ...
Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback